Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer

ObjectiveThis study a to evaluate the cost-effectiveness of ramucirumab plus paclitaxel as a switch maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer, from the perspective of the Chinese healthcare system, to guide clinical decision-making and r...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Dong Li, Xue Zhao, Huixian Jia, Rong Cui, Afang Cao, Liman Huo
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-02-01
Serija:	Frontiers in Oncology
Teme:	cost-effectiveness analysis gastric cancer Markov model pharmacoeconomics ramucirumab
Online dostop:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1713870/full
Oznake:	Označite Brez oznak, prvi označite!